AGS Therapeutics Strenghtens its Patent Portfolio on Microalgae Extracelluar Vesicles (MEV) with an International Patent Application on Preparation and Uses of MEVs as a Universal Drug Delivery System
MEVs can be exo-loaded with all kinds of therapeutics for delivery through multiple modes of administration, providing the potential to overcome current challenges faced by other delivery systems.
PARIS, FRANCE, May 8, 2023 – AGS Therapeutics, a preclinical stage biotech company pioneering microalgae extracellular vesicles (MEV) as a new delivery system for innovative therapeutic treatments, announced the recent publication of its International Patent Application WO2023/001894 (PCT/EP2022/070371) entitled Extracellular Vesicles from Microalgae, their Prepatation and Uses.
“MEVs can be efficiently loaded with a variety of innovative payloads (including mRNA, siRNA, plasmid-DNA, ASO, peptides, and proteins) and deliver them to various specific tissues and organs, far beyond the liver and lungs” said AGS Chief Operating Officer Lila Drittanti.
The published patent application highlights the versatility of AGS’s breakthrough universal delivery system. As far as versatility, efficiency and ease of exo-loading are concerned, MEVs easily overcome many of the challenges met by current delivery systems based on synthetic lipid nanoparticles (LNPs) and mammalian extracellular vesicles.
“Leading programs in AGS’ R&D pipeline are set to reach the clinical stage in late 2025,” said AGS Chief Corporate Development Marie-Hélène Leopold. “By leveraging its breakthrough delivery system, AGS believes it can develop life-changing therapies and technologies that may have a transformative impact on the lives of patients worldwide”
AGS’ portfolio of Intellectual Property is managed by Stephanie Seidman, at Dentons’ LLC, San Diego (www.dentons.com/en/stephanie-seidman).
About AGS
AGS Therapeutics, based in Paris, France, is a biotech company pioneering the development of biomedicines based on extracellular vesicles from microalgae (MEV) that have been shown to be a safe, targeted and highly versatile delivery system for innovative biologics, such as mRNA, siRNA, DNA, plasmids, and proteins for a broad range of human diseases. AGS-M, the company’s subsidiary and a contract development and manufacturing organization, will produce the MEVs needed to support preclinical and clinical development of MEV-based product pipelines from AGS and from pharmaceutical companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a GRAS two-billion-year-old single-cell algae used for decades as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with simple cell culture techniques that are both eco-friendly and easily scalable. Through strategic partnerships and a commitment to scientific excellence, the company aims to challenge the drug delivery landscape and improve the lives of patients across the globe.
For more information visit www.ags-tx.com and www.ags-m.com.
Forward looking statement
This announcement may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this communication.
Contacts - US:
Dan Eramian
Opus Biotech Communications
+1 425-306-8716
Charles Craig
Opus Biotech Communications
+1 404-245-0591
Contacts - Europe:
Ana Vega
Markets & Listing
+33 (0)6 88 57 05 77
Marie-Hélène Leopold
AGS Therapeutics
+33 (0)6 07 16 55 01
